Nivedita Sharma, MD
Internal Medicine · Jackson, NJNPI 1932134855
Payments from drug & device makers
Across 97 payments — averaging $16.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$267
- Novartis$126
- Astellas Pharma US Inc$124
- AbbVie$123
- Pfizer$117
- Novo Nordisk$112
- plus $700 from 22 others
What the payments were for
- Food & beverage$1,46994%
- Education$1006%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 16 | $267 |
| Novartis | 8 | $126 |
| Astellas Pharma US Inc | 3 | $124 |
| AbbVie(2 entities) | 9 | $123 |
| Pfizer | 8 | $117 |
| Novo Nordisk | 8 | $112 |
| AstraZeneca | 6 | $88 |
| Almatica Pharma LLC | 4 | $64 |
| Kowa Pharmaceuticals America, Inc. | 4 | $56 |
| Lilly USA, LLC | 4 | $55 |
| Amarin Pharma, Inc. | 4 | $53 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $49 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| Eisai Inc. | 2 | $29 |
| Exact Sciences | 1 | $29 |
| Alkermes, Inc. | 2 | $27 |
| GSK | 2 | $27 |
| Amgen | 2 | $26 |
| Indivior Inc. | 1 | $21 |
| Philips North America LLC | 1 | $19 |
| Bayer | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
| Biogen | 1 | $16 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Radius Health, Inc. | 1 | $15 |
| Merck | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
How this compares
$1,569 in reported general payments places this provider in the 70th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 308 | $148,018 |
| OzempicSemaglutide | 59 | $80,083 |
| JardianceEmpagliflozin | 99 | $71,293 |
| JanuviaSitagliptin Phosphate | 69 | $52,737 |
| XareltoRivaroxaban | 72 | $41,061 |
| VraylarCariprazine Hcl | 37 | $39,760 |
| PerserisRisperidone | 11 | $35,841 |
| MounjaroTirzepatide | 23 | $28,638 |
| MyrbetriqMirabegron | 45 | $26,433 |
| EntrestoSacubitril/Valsartan | 42 | $24,645 |
| RybelsusSemaglutide | 15 | $21,633 |
| VivitrolNaltrexone Microspheres | 11 | $20,296 |
| Nurtec OdtRimegepant Sulfate | 12 | $18,717 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $13,651 |
| FarxigaDapagliflozin Propanediol | 20 | $13,581 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Nurtec Odt | $117 | $166,735320 claims |
| Novo NordiskOzempic, Rybelsus | $112 | $101,71674 claims |
| MerckJanuvia, Janumet Xr | $15 | $61,88091 claims |
| AbbVieVraylar, Linzess | $123 | $45,95748 claims |
| Johnson & JohnsonXarelto | $267 | $41,06172 claims |
| GSKTrelegy Ellipta, Arexvy, Breo Ellipta, Incruse Ellipta | $27 | $39,29490 claims |
| Indivior Inc.Perseris | $21 | $35,84111 claims |
| Lilly USA, LLCMounjaro | $55 | $28,63823 claims |
| Astellas Pharma US IncMyrbetriq | $124 | $26,43345 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Lokelma | $88 | $26,15949 claims |
| NovartisEntresto | $126 | $24,64542 claims |
| Alkermes, Inc.Vivitrol | $27 | $20,29611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Jackson
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
- Helio PedroNewark$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.